University of California

Marcus Aaron Horwitz

Gunter Harth

Daniel L Clemens

Bai-Yu Lee Clemens

Michael V Tullius

Qingmei Jia

Chih-Ming Ho

Lawrence D Horwitz

Xianting Ding

Aleidy Marlene Silva Vite

Günter Harth

Theodore Kee

G&uuml;nter Harth

Bradford W Gibson

Jeffrey I Zink

Joseph Reeve

Bastian Ruehle

Bai-Yu Lee

A method of immunizing a susceptible host against a pathogen comprising administering to the host a vaccine that comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS &#x394;capB), wherein the LVS &#x394;capB expresses an antigen of at least one pathogen from Table 1; or administering to the host a vaccine that comprises an attenuatedexpressing the antigen of the pathogen from Table 1; or administering to the host a prime vaccine and a heterologous booster vaccine where the prime vaccine comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS &#x394;capB), wherein the LVS &#x394;capB expresses an antigen of at least one pathogen from Table 1 and the heterologous booster vaccine comprises an attenuatedexpressing the antigen of the pathogen from Table 1.

Safe potent single platform vaccine against Tier 1 select agents and other pathogens

In various embodiments nanoparticle drug delivery vehicles are provided that specifically deliver a cargo to a target pathogenic organism. In certain embodiments the drug delivery vehicle comprises a mesoporous silica nanoparticle comprising a plurality of pores and an outer surface through which the pores are disposed; a cargo disposed in the pores; one or more antigens attached to the surface of the nanoparticle; an antibody that specifically binds the antigens and are bound to the antigens, wherein the antibody inhibits diffusion of the cargo out of the pores and permit release of the cargo when the drug delivery vehicle is in the presence of the antigen or a pathogen displaying the antigen.

Pathogen-specific cargo delivery and diagnostic platform based on mesoporous silica nanoparticles

The present invention is directed to methods of treating tuberculosis by providing a pharmaceutically effective amount of a combination of drug compounds.

Multi-drug therapies for tuberculosis treatment

Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such asin humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases.

Live recombinant booster vaccine against tuberculosis

Recombinant immunogenic compositions, and methods for the manufacture and use, are provided for the prevention and treatment of intracellular pathogen diseases in humans and animals. The recombinant immunogenic compositions express high levels of recombinant proteins in vectors that do not harbor an antibiotic resistance marker ('unmarked').

Unmarked recombinant intracellular pathogen immunogenic compositions expressing high levels of recombinant proteins

The disclosure relates generally to an antigenic composition useful for immunization against tularemia. The disclosure is a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia.

Vaccines against tularemia

Immunogenic compositions comprising recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens and immunostimulatory molecules are provided. Exemplary immunogenic compositions include, but are not limited to, recombinant BCG expressingmajor extracellular proteins and immunostimulatory molecules.

Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use

Immunogenic compositions comprising recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens and immunostimulatory molecules are provided. Exemplary immunogenic compositions include, but are not limited to, recombinant BCG expressing Mycobacteria major extracellular proteins and immunostimulatory molecules.

The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia.

Methods and compositions for treating tularemia

Immunogenic compositions comprising growth regulatable recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, growth regulatable and growth limited recombinant attenuated intracellular pathogen immunogenic compositions.

Growth regulatable recombinant BCG compositions

Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinantexpressing the major extracellular non-fusion proteins ofand/or other intracellular pathogens. Other embodiments are provided wherein the recombinant attenuated intracellular pathogen is auxotrophic.

Recombinant intracellular pathogen immunogenic compositions and methods of use

Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacteria and/or other intracellular pathogens. Other embodiments are provided wherein the recombinant attenuated intracellular pathogen is auxotrophic.

Recombinant intracellular pathogen immunogenic compositions and methods for use

Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. The majorly abundant extracellular products may be characterized and distinguished by their respective N-terminal amino acid, amino acid, or DNA sequences. As the vaccines may comprise different combinations of the extracellular products, subunits thereof, or encoding nucleic acids, a broad range of effective immunotherapeutic compositions are provided by the present invention. In addition to other infectious agents, the vaccines so produced can be used to stimulate an effective immune response against intracellular pathogens and in particular

Growing community of inventors

Los Angeles, CA, United States of America

Marcus Aaron Horwitz